Individualized glycaemic targets and pharmacotherapy in type 2 diabetes

Research output: Contribution to journalArticle

Abstract

The Global Partnership for Effective Diabetes Management, established to provide practical guidance to improve patient outcomes in diabetes, has developed and modified recommendations to improve glycaemic control in type 2 diabetes. The Global Partnership advocates an individualized therapeutic approach and, as part of the process to customize therapy, has previously identified specific type 2 diabetes patient subgroups that require special consideration. This article builds on earlier publications, expanding the scope of practical guidance to include newly diagnosed individuals with complications and women with diabetes in pregnancy. Good glycaemic control remains the cornerstone of managing type 2 diabetes, and plays a vital role in preventing or delaying the onset and progression of diabetic complications. Individualizing therapeutic goals and treatments to meet glycaemic targets safely and without delay remains paramount, in addition to a wider programme of care to reduce cardiovascular risk factors and improve patient outcomes.
Original languageEnglish
Pages (from-to)397-409
Number of pages13
JournalDiabetes and Vascular Disease Research
Volume10
Issue number5
DOIs
Publication statusPublished - Sep 2013

Fingerprint

Type 2 Diabetes Mellitus
Drug Therapy
Pregnancy in Diabetics
Diabetes Complications
Therapeutics

Keywords

  • glycaemic targets
  • global partnership
  • individualized therapy
  • type 2 diabetes
  • HbA1c

Cite this

@article{2b5331d48c4f4c86851f371171f82b28,
title = "Individualized glycaemic targets and pharmacotherapy in type 2 diabetes",
abstract = "The Global Partnership for Effective Diabetes Management, established to provide practical guidance to improve patient outcomes in diabetes, has developed and modified recommendations to improve glycaemic control in type 2 diabetes. The Global Partnership advocates an individualized therapeutic approach and, as part of the process to customize therapy, has previously identified specific type 2 diabetes patient subgroups that require special consideration. This article builds on earlier publications, expanding the scope of practical guidance to include newly diagnosed individuals with complications and women with diabetes in pregnancy. Good glycaemic control remains the cornerstone of managing type 2 diabetes, and plays a vital role in preventing or delaying the onset and progression of diabetic complications. Individualizing therapeutic goals and treatments to meet glycaemic targets safely and without delay remains paramount, in addition to a wider programme of care to reduce cardiovascular risk factors and improve patient outcomes.",
keywords = "glycaemic targets , global partnership, individualized therapy, type 2 diabetes, HbA1c",
author = "Bailey, {Clifford J.} and Pablo Aschner and {del Prato}, James and James LaSalle and Linong Ji and Stephan Matthaei",
year = "2013",
month = "9",
doi = "10.1177/1479164113490765",
language = "English",
volume = "10",
pages = "397--409",
journal = "Diabetes and Vascular Disease Research",
issn = "1479-1641",
publisher = "SAGE",
number = "5",

}

Individualized glycaemic targets and pharmacotherapy in type 2 diabetes. /.

In: Diabetes and Vascular Disease Research, Vol. 10, No. 5, 09.2013, p. 397-409.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Individualized glycaemic targets and pharmacotherapy in type 2 diabetes

AU - Bailey, Clifford J.

AU - Aschner, Pablo

AU - del Prato, James

AU - LaSalle, James

AU - Ji, Linong

AU - Matthaei, Stephan

PY - 2013/9

Y1 - 2013/9

N2 - The Global Partnership for Effective Diabetes Management, established to provide practical guidance to improve patient outcomes in diabetes, has developed and modified recommendations to improve glycaemic control in type 2 diabetes. The Global Partnership advocates an individualized therapeutic approach and, as part of the process to customize therapy, has previously identified specific type 2 diabetes patient subgroups that require special consideration. This article builds on earlier publications, expanding the scope of practical guidance to include newly diagnosed individuals with complications and women with diabetes in pregnancy. Good glycaemic control remains the cornerstone of managing type 2 diabetes, and plays a vital role in preventing or delaying the onset and progression of diabetic complications. Individualizing therapeutic goals and treatments to meet glycaemic targets safely and without delay remains paramount, in addition to a wider programme of care to reduce cardiovascular risk factors and improve patient outcomes.

AB - The Global Partnership for Effective Diabetes Management, established to provide practical guidance to improve patient outcomes in diabetes, has developed and modified recommendations to improve glycaemic control in type 2 diabetes. The Global Partnership advocates an individualized therapeutic approach and, as part of the process to customize therapy, has previously identified specific type 2 diabetes patient subgroups that require special consideration. This article builds on earlier publications, expanding the scope of practical guidance to include newly diagnosed individuals with complications and women with diabetes in pregnancy. Good glycaemic control remains the cornerstone of managing type 2 diabetes, and plays a vital role in preventing or delaying the onset and progression of diabetic complications. Individualizing therapeutic goals and treatments to meet glycaemic targets safely and without delay remains paramount, in addition to a wider programme of care to reduce cardiovascular risk factors and improve patient outcomes.

KW - glycaemic targets

KW - global partnership

KW - individualized therapy

KW - type 2 diabetes

KW - HbA1c

UR - http://www.scopus.com/inward/record.url?scp=84882323601&partnerID=8YFLogxK

UR - http://dvr.sagepub.com/content/10/5/397

U2 - 10.1177/1479164113490765

DO - 10.1177/1479164113490765

M3 - Article

AN - SCOPUS:84882323601

VL - 10

SP - 397

EP - 409

JO - Diabetes and Vascular Disease Research

JF - Diabetes and Vascular Disease Research

SN - 1479-1641

IS - 5

ER -